8-K/A: Current report filing
Published on September 8, 2010
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K/A
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported)
September
1, 2010
NEOGENOMICS,
INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
333-72097
|
74-2897368
|
|
|
(State
or other jurisdiction of
|
(Commission
File Number)
|
(I.R.S.
Employer
|
|
|
incorporation)
|
Identification
No.)
|
||
|
12701 Commonwealth
Drive, Suite 9, Fort Myers, Florida
(Address
of principal executive offices)
|
33913
(Zip
Code)
|
||
(239)
768-0600
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
□
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
□
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
□
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
□
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item
5.02.
|
Departure
of Directors or Certain Officers; Election of Directors;Appointment of
Certain Officers; Compensatory Arrangements of
CertainOfficers.
|
Effective
as of September 1, 2010, the Company terminated its employment arrangement with
Jack G. Spitz as Vice President of Operations. In accordance with our
agreement we will pay Mr. Spitz’s base salary and maintain his employee benefits
for a six (6) month period from the date of the termination
notice. Mr. Spitz’s termination was part of a broader reorganization
of the Company’s operations, which we estimate will result in approximately $1.5
million of annual cost savings.
(a) Not
applicable
(b) Not
applicable
(c) Not
applicable
(d) Not
applicable
- 2
- -
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| NEOGENOMICS, INC. | |||
|
|
By:
|
/s/ Douglas M. VanOort | |
|
Douglas
M. VanOort
Chairman
and Chief Executive Officer
|
|||
|
Date:
September 8, 2010
|
- 3
- -